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Abstract: 33 
Background: Central adjudication of outcomes is common for randomised trials and should control 34 
for differential misclassification. However, few studies have estimated the cost of the adjudication 35 
process. 36 
Methods: We estimated the cost of adjudicating the primary outcome in nine randomised stroke trials 37 
(25,436 participants). The costs included adjudicators’ time, direct payments to adjudicators, and co-38 
ordinating centre costs (e.g. uploading cranial scans and general set-up costs). The number of events 39 
corrected after adjudication was our measure of benefit. We calculated cost per corrected event for 40 
each trial and in total. 41 
Results: The primary outcome in all nine trials was either stroke or a composite that included stroke. 42 
In total, the adjudication process associated with this primary outcome cost in excess of £100,000 for 43 
a third of the trials (3/9). Mean cost per event corrected by adjudication was £2295.10 (standard 44 
deviation: £1482.42). 45 
Conclusions: Central adjudication is a time-consuming and potentially costly process. These costs 46 
need to be considered when designing a trial and should be evaluated alongside the potential benefits 47 
adjudication brings to determine whether they outweigh this expense. 48 
Keywords: Adjudication, stroke, clinical trial  49 
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Introduction: 50 
In randomised stroke trials, central adjudication of outcomes is common[1]. Adjudicators are typically 51 
blinded independent experts who review individual participant data and provide an assessment of 52 
outcome(s). Clinicians at local sites often assess the same outcomes but these data are commonly 53 
discarded. Central adjudication should reduce both random and systematic bias, but studies have 54 
shown that it has limited impact on the estimated treatment effect in randomised trials[1-3]. Thus, it is 55 
important to estimate the cost of the adjudication process, in order to establish whether the cost 56 
outweighs the perceived benefit of the process.  57 
The cost of adjudication could be estimated as the direct cost paid to the adjudicator, which is often a 58 
menial amount (£10-15 per adjudication). However, this does not take into account the time it takes 59 
the adjudicator to undertake their assessment of the individual participant data. Furthermore, 60 
preparing data for the adjudicators, blinding and obtaining source information and general set-up 61 
costs are other expenses associated with the adjudication process that are borne by the co-ordinating 62 
centre (often a clinical trials unit). Thus, the cost of the adjudication process can be made up from (1) 63 
direct costs paid to the adjudicators; (2) time costs of the adjudicators; and (3) co-ordinating centre 64 
costs. 65 
The aim of this study was to estimate the cost of central adjudication in randomised stroke trials and 66 
present this cost in terms of the number of events corrected by the central adjudication process.  67 
 68 
Methods: 69 
Data Collection 70 
Authors of stroke trials included in a systematic review[1] were invited to provide data on the cost of 71 
outcome adjudication in an online questionnaire (see Supplemental Material, Cost of Adjudication 72 
Questionnaire). Data collected included time required to adjudicate events, adjudicators’ approximate 73 
salary in today’s costs and how disagreements were handled.  74 
Benefit of Adjudication 75 
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Our measure of benefit of the adjudication process was the number of events corrected after 76 
adjudication. This outcome provides an estimate of the agreement between the adjudicators and site 77 
investigators and quantifies the extent to which the adjudication process changes the trial outcome. 78 
However, this measure does not take into account whether the adjudication process impacts on the 79 
treatment effect estimate. We collected the number of events corrected after adjudication in our 80 
previous systematic review[1].  81 
Cost of Adjudication 82 
All costs were taken from a societal perspective and were reported in various currencies (Australian 83 
dollars, Euros, Pounds Sterling and New Zealand Dollars). If costs were not entered as pounds 84 
sterling, then all other currencies were converted into pounds sterling on 16th May 2019.  85 
We calculated adjudicator hourly salary assuming that adjudicators worked 1680 hours a year (40 86 
hours a week for 42 weeks of the year). Total time was determined using the amount of time it took 87 
for each adjudication, the number of events adjudicated and whether events were adjudicated 88 
multiple times. In addition to staff salary costs assumed to be borne by employers rather than study 89 
funders, we also assumed that adjudicators were directly paid £10 per event from study funds. This is 90 
not paid in all studies; however, it enables a comparison between studies and where paid, is typical of 91 
the amount in UK studies. Costs of resolving disagreements was based on staff time only. 92 
For each study, we assumed a fixed set-up cost to create a website for data sharing (brain scans, 93 
video footage etc.) and for adjudicators to submit their final assessments. We estimated this to require 94 
40 hours of a database programmer (cost £650). We also assumed that each adjudicated event 95 
required four hours of administrative time at the co-ordinating centre (cost £40 per adjudicated event).  96 
Statistical Analysis 97 
Continuous variables were summarised with mean and standard deviation, or median and 98 
interquartile range. Categorical variables were described with frequency counts and percentages. The 99 
cost per event corrected was determined for each trial and for all trials. 100 
 101 
Results: 102 
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Authors from nine trials, comprising 25,436 participants, completed the questionnaire and these nine 103 
trials are included in this study[4-12] (Table 1). All outcomes adjudicated were either stroke or a 104 
composite including stroke, with two trials including transient ischaemic attack as part of their 105 
outcome of stroke (See Supplementary Material, Supplementary Table I). In the majority of the trials 106 
(7/9, 77%) adjudicators reviewed only those events identified by the site investigators, but for two of 107 
the studies adjudicators assessed a larger number of events, by adjudicating either suspected events 108 
or all participants (See Supplementary Material, Supplementary Table I).The time taken per 109 
adjudication range from five minutes to two hours. However, the trial with the lowest time had three 110 
adjudicators assess each event (Table 2). All other trials assessed each event either once or twice. 111 
The trial with highest adjudicator salary cost was around twice that of the lowest.  112 
Three of the trials (33%) had no disagreements (see Supplementary Material, Supplementary Table 113 
II). For trials that had disagreements between adjudicators, the cost and time associated with this was 114 
far less than that associated with the original adjudication (Table 3). Two studies had no events 115 
corrected after adjudication, although the total cost of the adjudication process for both of these was 116 
less than £4,000. Three trials had a total estimated cost of the adjudication process in excess of 117 
£100,000. On average, across the seven trials with corrected events, adjudication cost £2,295.10 per 118 
event corrected (standard deviation: £1482.42).   119 
Discussion: 120 
In this analysis of nine randomised trials we found that, on average, adjudication costs approximately 121 
£2,300 per corrected event, with the total cost of adjudication exceeding £100,000 for three trials. Our 122 
study assumed a fixed cost of £40 per adjudication for the co-ordinating centre, as it was not possible 123 
to collect accurate data retrospectively on a trial-by-trial basis. Another study estimated the co-124 
ordinating centre cost for the adjudication process in a thromboprophylaxis trial, to be approximately 125 
£55 per adjudicated event[13] compared to our assumption of £40. Thus, we may have marginally 126 
underestimated the total cost of the adjudication process.  127 
The nine trials included in this study all had binary primary outcomes, and when these were 128 
composites, they were constructed from binary components. There may be different types of 129 
outcomes that have greater or worse cost-benefit of adjudication than the outcomes described in this 130 
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study. For example, outcomes with greater objectivity, such as disabling stroke, may have less need 131 
for adjudication when compared to more subjective outcomes, such as functional status measured on 132 
the modified Rankin Scale or causality of adverse events[14]. In addition, the method of adjudication 133 
could have large cost-benefit implications. For studies where adjudicators only assess site-reported 134 
events, the cost will be lower than studies in which all participants are adjudicated. However, when 135 
adjudicators only assess site-reported events, the adjudicators cannot identify additional events that 136 
could have been missed by the site investigators, potentially limiting the benefit of adjudication. 137 
Furthermore, the blinding status of the site investigators has the potential to influence the benefit that 138 
can be gained from adjudication[15], and this information should be used when designing a clinical trial 139 
to understand the potential costs and benefits adjudication can bring.  140 
This study has a number of limitations. Firstly, the nine trials included span a 30-year time interval and 141 
cover a range of academic and industry funded trials, as well as including funding agencies that have 142 
varied sources of financial support (e.g. charities, government agencies). Therefore, the variability in 143 
these factors may have contributed to the disparity seen between the time taken for adjudication, 144 
which may have influenced the estimated cost of adjudication in this study. Secondly, this study relies 145 
on retrospectively collected cost data. Some of the trials included in this study performed their 146 
adjudications decades ago, so it is possible that this data is not as accurate as data collected 147 
prospectively. However, this is the first study that we are aware of that has attempted to estimate the 148 
entire cost of the adjudication process.  149 
As eluded to above, further research is warranted that prospectively collects the costs of central 150 
adjudication in an ongoing trial. A previous study showed that adjudications can take months to 151 
complete[14], and a prospective study could accurately measure the time taken for the multitude of 152 
processes that are involved in implementing adjudication in a clinical trial. Furthermore, combining 153 
cost data with the approach of Kahan and colleagues[16] could give further understanding to the cost-154 
benefit of increasing the number of adjudicators or varying the method of adjudication.   155 
To conclude, central adjudication has been shown to control for differential misclassification and is 156 
important for trials where blinding is inadequate or impossible[15]. However, it can be costly, and these 157 
costs need to be estimated when designing a trial to evaluate whether the benefits of central 158 
adjudication outweigh the potential expense.  159 
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Tables: 
 
Table 1: Characteristics of included trials 
 
  
 Included (n=9) 
Year of main trial publication  
1990-2000 2 (22%) 
2001-2005 1 (11%) 
2006-2010 2 (22%) 
2011-2015 2 (22%) 
2016-2018 2 (22%) 
Study design  
Parallel 8 (89%) 
Factorial 1 (11%) 
Type of trial  
Primary prevention 1 (11%) 
Secondary prevention 6 (67%) 
Acute stroke 2 (22%) 
Participants randomised  
Mean (SD) 2826 (2744) 
Median [25th, 75th centile] 2739 [449, 3096] 
Min, Max 129, 8164 
No. of sites  
Mean (SD) 86 (49) 
Median [25th, 75th centile] 79 [50, 123] 
Min, Max 17, 172 
Intervention  
Drug 6 (67%) 
Surgery/procedure 2 (22%) 
Other 1 (11%) 
Comparator  
Placebo 2 (22%) 
Standard care 6 (67%) 
Surgery/procedure 1 (11%) 
Primary outcome  
Stroke 6 (67%) 
Composite including stroke 3 (33%) 
Blinding status of site 
investigators 
 
Blind to treatment allocation 4 (44%) 
Not blind to treatment allocation 5 (56%) 
Page 11 
 
Table 2: Time taken for adjudication and dealing with disagreements 
 
 
 
 
 
 
 
 
*Calculated as: Cost of adjudication = (Total time for adjudication)*(Adjudicator hourly salary) + [(Events adjudicated)*Number of adjudication per 
event)*(£10)] 
  
Trial name Events 
adjudicated 
Number of 
adjudications 
per event 
Time per 
adjudication 
(minutes) 
Total time for 
adjudication 
(hours) 
Adjudicator 
hourly salary 
Cost of 
adjudication* 
CABACS 34 Once 10  5.7 £67.62 £723.18 
ESPRIT 440 Three 5  110  £62.40 £20064 
FASTEST 24 Once 45  18  £70.16 £1502.88 
HAEST 93 Once 15 23.25 £47.62 £2037.17 
J-STARS 239 Once 30  119.5  £47.62 £8080.59 
NASCET 436 Twice 120  1744  £47.62 £91769.28 
PROGRESS 992 Once 15  248  £48.22 £21878.56 
TARDIS 1656 Twice 10  552  £49.40 £60388.80 
VITATOPS 1260 Once 20  420  £96.40 £53088 
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Table 3: Cost of adjudication per corrected event by included trial 
Trial name Coordinating 
centre cost* 
Adjudication 
cost 
Disagreement 
cost 
Total cost Number of events corrected 
after adjudication 
Cost per 
corrected event 
CABACS £2010 £723.18 £0 £2733.18 0 NA 
ESPRIT £18250 £20064 £114.40 £38428.40 51 £753.50 
FASTEST £1610 £1502.88 £631.44 £3744.32 0 NA 
HAEST £4370 £2037.17 £0 £6407.17 2 £3203.58 
J-STARS £10210 £8080.59 £2381 £20671.59 10 £2067.16 
NASCET £18090 £91769.28 £1285.74 £111145.02 27 £4116.48 
PROGRESS £40330 £21878.56 £0 £62208.56 98 £634.78 
TARDIS £66890 £60388.80 £8348.60 £135627.40 34 £3989.04 
VITATOPS £51050 £53088 £1253.20 £105391.20 81 £1301.13 
       
Mean (SD)† 
     
£2295.10 
(1482.42) 
Median†      £2067.16 
Min†      £634.78 
Max†      £4116.48 
*Coordinating centre cost includes £650 set-up cost and £40 cost per event 
†Summary statistics do not include CABACS or FASTEST 
 
 
 
 
 
